Tag Archive for: data

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines  Positive results reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS 9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused […]

Read more

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

/in

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expression data shows upregulation of innate immunity pathways Tumor regressions observed at all dose levels, 60-200 mg TIW 11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient

/in

Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]

Read more

Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024

/in

– Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation  – Poster presentation on new data highlighting the Company’s discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use  Edinburgh and London, UK, 29 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering […]

Read more

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

/in

Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX model Data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme […]

Read more